Macquarie Group’s Concert Pharmaceuticals, Inc. CNCE Stock Holding History

Macquarie Group’s Portfolio CNCE Stock Details CNCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-2,000	Closed	-$25K	–	2152
2018 Q4	$25K	Sell	2,000 -22,900	-92%	-$316K	﹤0.01%	1748
2018 Q3	$370K	Sell	24,900 -24,600	-50%	-$387K	﹤0.01%	1361
2018 Q2	$833K	Buy	49,500 +23,500	+90%	+$456K	﹤0.01%	1231
2018 Q1	$595K	Buy	+26,000	New	+$578K	﹤0.01%	1331

Other funds holding CNCE

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

ISL

Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Macquarie Group's CNCE Position: Q1 2019 in Review

Macquarie Group sold out of Concert Pharmaceuticals, Inc. (CNCE) in Q1 2019, closing a stake of 2,000 shares — an estimated $25K sold.

Macquarie Group first reported a position in CNCE in Q1 2018 and held it in 4 quarters. The position peaked at $833K in Q2 2018. 92 funds tracked by Wall St. Rank hold CNCE as of Q1 2019.

Macquarie Group reported no remaining Concert Pharmaceuticals, Inc. position as of Q1 2019 after selling out during the quarter.
Macquarie Group sold 2,000 Concert Pharmaceuticals, Inc. shares in Q1 2019, an estimated $25K.
Macquarie Group first reported a position in Concert Pharmaceuticals, Inc. in Q1 2018 and held it in 4 quarters.
Macquarie Group's Concert Pharmaceuticals, Inc. position peaked at $833K in Q2 2018.
92 funds tracked by Wall St. Rank held Concert Pharmaceuticals, Inc. as of Q1 2019.

Based on Macquarie Group's 13F filing for Q1 2019, filed 15 May 2019.